Total submissions: 12
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Counsyl | RCV000409888 | SCV000487481 | likely pathogenic | Carnitine palmitoyl transferase II deficiency, myopathic form | 2016-01-07 | criteria provided, single submitter | clinical testing | |
Counsyl | RCV000009530 | SCV000487482 | likely pathogenic | Carnitine palmitoyl transferase II deficiency, severe infantile form | 2016-01-07 | criteria provided, single submitter | clinical testing | |
Counsyl | RCV000408956 | SCV000487483 | likely pathogenic | Carnitine palmitoyl transferase II deficiency, neonatal form | 2016-01-07 | criteria provided, single submitter | clinical testing | |
Labcorp Genetics |
RCV000202546 | SCV000632607 | pathogenic | Carnitine palmitoyltransferase II deficiency | 2023-12-10 | criteria provided, single submitter | clinical testing | This sequence change replaces tyrosine, which is neutral and polar, with cysteine, which is neutral and slightly polar, at codon 120 of the CPT2 protein (p.Tyr120Cys). This variant is present in population databases (rs121918528, gnomAD 0.03%). This missense change has been observed in individual(s) with clinical features of carnitine palmitoyltransferase II deficiency (PMID: 10862092, 16996287, 18550408; Invitae). In at least one individual the data is consistent with being in trans (on the opposite chromosome) from a pathogenic variant. It has also been observed to segregate with disease in related individuals. ClinVar contains an entry for this variant (Variation ID: 8968). Advanced modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) performed at Invitae indicates that this missense variant is expected to disrupt CPT2 protein function with a positive predictive value of 80%. Experimental studies have shown that this missense change affects CPT2 function (PMID: 16615913). For these reasons, this variant has been classified as Pathogenic. |
Fulgent Genetics, |
RCV000762942 | SCV000893365 | likely pathogenic | Carnitine palmitoyl transferase II deficiency, severe infantile form; Carnitine palmitoyl transferase II deficiency, myopathic form; Carnitine palmitoyl transferase II deficiency, neonatal form; Encephalopathy, acute, infection-induced, susceptibility to, 4 | 2022-02-16 | criteria provided, single submitter | clinical testing | |
Revvity Omics, |
RCV001781212 | SCV002023387 | likely pathogenic | not provided | 2021-03-04 | criteria provided, single submitter | clinical testing | |
MGZ Medical Genetics Center | RCV000409888 | SCV002579622 | pathogenic | Carnitine palmitoyl transferase II deficiency, myopathic form | 2021-11-24 | criteria provided, single submitter | clinical testing | |
Genome- |
RCV000009530 | SCV004179307 | likely pathogenic | Carnitine palmitoyl transferase II deficiency, severe infantile form | 2023-04-11 | criteria provided, single submitter | clinical testing | |
Baylor Genetics | RCV003473068 | SCV004211048 | pathogenic | Encephalopathy, acute, infection-induced, susceptibility to, 4 | 2024-03-22 | criteria provided, single submitter | clinical testing | |
OMIM | RCV000009530 | SCV000029748 | pathogenic | Carnitine palmitoyl transferase II deficiency, severe infantile form | 2008-08-01 | no assertion criteria provided | literature only | |
Gene |
RCV000202546 | SCV000153657 | not provided | Carnitine palmitoyltransferase II deficiency | no assertion provided | literature only | ||
Natera, |
RCV000202546 | SCV001461215 | likely pathogenic | Carnitine palmitoyltransferase II deficiency | 2020-09-16 | no assertion criteria provided | clinical testing |